Institute of Tropical Medicine Antwerp
Foundation of Public Utility

Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi; results of a drug resistance survey

DSpace/Manakin Repository

Show simple item record

dc.contributor.author Sanders, M. en_US
dc.contributor.author Van Deun, A. en_US
dc.contributor.author Ntakirutimana, D. en_US
dc.contributor.author Masabo, J. P. en_US
dc.contributor.author Rukundo, J. en_US
dc.contributor.author Rigouts, L. en_US
dc.contributor.author Fissette, K. en_US
dc.contributor.author Portaels, F. en_US
dc.date.accessioned 2007-12-06T14:48:06Z
dc.date.available 2007-12-06T14:48:06Z
dc.date.issued 2006 en_US
dc.identifier.issn 1027-3719 en_US
dc.identifier.other ITG-M2A en_US
dc.identifier.other ITG-M6A en_US
dc.identifier.other ITG-M7B en_US
dc.identifier.other ITG-MLA en_US
dc.identifier.other MICRO en_US
dc.identifier.other U-MYCOB en_US
dc.identifier.other JIF en_US
dc.identifier.other ABSTRACT en_US
dc.identifier.uri http://hdl.handle.net/10390/1943
dc.description.abstract SETTING: Bujumbura, Burundi. OBJECTIVES: To determine resistance levels of Mycobacterium tuberculosis (TB) to the main anti-tuberculosis drugs after 11 years of a DOTS programme using a WHO-recommended partially intermittent 6-month rifampicin (RMP) first-line regimen and fixed-dose drug combinations (FDCs). DESIGN: Drug susceptibility testing of systematic samples of M. tuberculosis isolated from newly registered sputum smear-positive cases in the capital during a 15-month period (2002-2003). RESULTS: Of 496 strains from new cases, 16.1% showed resistance to any drug, 6.3% to isoniazid (INH), 2.0% to RMP (1.4% multidrug-resistant TB [MDR-TB]), 13.3% to streptomycin and 1.6% to ethambutol. Among 69 strains from previously treated cases, the prevalence of resistance was 30%, 19%, 15% (12% MDR-TB strains), 25% and 6%, respectively. CONCLUSION: Levels of drug resistance in Bujumbura are higher than average for Africa, despite long-term use of the DOTS strategy with FDCs and a ban on sales of TB drugs. Most worrying is the appearance of MDR-TB and RMP-resistant, INH-susceptible strains in new cases. Although a survey cannot prove that high HIV prevalence, elevated levels of resistance to some other drugs and irregular intake allowed acquisition of drug resistance, the effectiveness and safety of 6-month regimens with (partially) intermittent RMP throughout under such conditions should be investigated. en_US
dc.language English en_US
dc.publisher International Union Against Tuberculosis And Lung Disease
dc.subject Bacterial diseases en_US
dc.subject Tuberculosis en_US
dc.subject Mycobacterium tuberculosis en_US
dc.subject Drug resistance en_US
dc.subject Rifampicin en_US
dc.subject Burundi en_US
dc.subject Africa, Central en_US
dc.title Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi; results of a drug resistance survey en_US
dc.type Article en_US
dc.citation.issue 2 en_US
dc.citation.jtitle International Journal of Tuberculosis and Lung Disease en_US
dc.citation.volume 10 en_US
dc.citation.pages 178-183 en_US
dc.publisher.place Paris
dc.identifier.pmid http://www.ncbi.nlm.nih.gov/pubmed/16499257
dc.citation.jabbreviation Int J Tuberc Lung Dis en_US


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record